Company: CDLX
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001666071-25-000069
Chunk: 101

Company: Cardlytics, Inc.
Filing Date: 2025-05-07
Form: 10-Q
Item: Item 1
Chunk 101
---
AccumulatedDeficitTotal Common Stock SharesAmountBalance – December 31, 202451,257 $10 $1,366,958 $3,601 $(1,300,576)$69,993 Stock-based compensation— — 9,734 — — 9,734 Settlement of restricted stock918 — — — — — Other comprehensive loss— — — (2,355)— (2,355)Net Loss— — — — (13,282)(13,282)Balance – March 31, 202552,175 $10 $1,376,692 $1,246 $(1,313,858)$64,090 

Three Months Ended March 31, 2024:

  AdditionalPaid-InCapitalAccumulatedOtherComprehensive IncomeAccumulatedDeficitTotal Common Stock SharesAmountBalance – December 31, 202339,728 $9 $1,243,594 $2,467 $(1,111,272)$134,798 Exercise of common stock options3 — 5 — — 5 Stock-based compensation— — 12,256 — — 12,256 Settlement of restricted stock943 — — — — — Issuance of common stock, net of issuance costs - Settlement Agreement (as defined below)3,592 — 27,451 — — 27,451 Issuance of common stock, net of issuance costs - ATM Offering Program (as defined below)3,908 — 48,322 — — 48,322 Other comprehensive income— — — 580 — 580 Net Loss— — — — (24,275)(24,275)Balance – March 31, 202448,174 $9 $1,331,628 $3,047 $(1,135,547)$199,137 

See notes to the condensed consolidated financial statements6

CARDLYTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(Amounts in thousands)

 Three Months EndedMarch 31, 20252024Operating activitiesNet Loss$(13,282)$(24,275)Adjustments to reconcile net